Five-year outcomes of psilocybin-assisted therapy for Major Depressive Disorder
Journal of Psychedelic Studies · 24.11.2025 · 9 (4) · 320-329
DOI: 10.1556/2054.2025.00461 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Psychedelic Studies, erschienen am 24.11.2025. Verfasst von Alan K. Davis und 11 weiteren Autor:innen. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Major Depressive Disorder (MDD) is a leading cause of disability and economic loss, with high recurrence and treatment resistance. Psilocybin-assisted therapy (PAT) shows promise in reducing depressive symptoms, but long-term effects are unknown. We aimed to determine the long-term safety and efficacy of PAT for MDD over a five-year follow-up period.
Methods
Individuals who previously participated in an RCT studying the effects of PAT for patients with MDD were contacted for a long-term follow-up (LTFU) study. This study uses a parallel convergent mixed methods design. Of the original 24 RCT participants, 21 enrolled in the LTFU study, with 18 (75%) completing it. For the six non-completers, baseline scores were used in quantitative analyses as conservative estimates. The primary outcome was clinician-rated change in depression severity from baseline to LTFU. Secondary outcomes included anxiety, functional impairment, and qualitative assessments of participants' experiences and mental health.
Results
Significant and sustained reductions in depression were observed, with 67% in remission for at least five years post-treatment. Anxiety and functional impairment also improved. Qualitative interviews revealed lasting positive changes in mindset, emotional health, and relationships. Participants reported enhanced empathy, self-acceptance, and improved interpersonal relationships. No severe adverse events were reported.
Conclusion
This study supports the long-term efficacy and safety of PAT in reducing depressive symptoms and improving mental health in patients with MDD. Further research is needed to determine if these findings can be replicated, and to explore the mechanisms behind the sustained benefits of PAT, potentially validating an approach that could transform the treatment of MDD.
Zitieren
APA
Davis, A. K., DellaCrosse, M. A., Sepeda, N. D., Levin, A. W., Cosimano, M., Shaub, H., Washington, T., Gooch, P. M., Gilead, S., Gaughan, S. J., Armstrong, S. B., & Barrett, F. S. (2025). Five-year outcomes of psilocybin-assisted therapy for Major Depressive Disorder. Journal of Psychedelic Studies, 9(4), 320-329. https://doi.org/10.1556/2054.2025.00461
Vancouver
Davis AK, DellaCrosse MA, Sepeda ND, Levin AW, Cosimano M, Shaub H, et al. Five-year outcomes of psilocybin-assisted therapy for Major Depressive Disorder. Journal of Psychedelic Studies. 2025;9(4):320-329. doi:10.1556/2054.2025.00461
BibTeX
@article{Davis2025,
author = {Davis, Alan K. and DellaCrosse, Meghan A. and Sepeda, Nathan D. and Levin, Adam W. and Cosimano, Mary and Shaub, Hillary and Washington, Taylor and Gooch, Peter M. and Gilead, Shoval and Gaughan, Skylar J. and Armstrong, Stacey B. and Barrett, Frederick S.},
title = {Five-year outcomes of psilocybin-assisted therapy for Major Depressive Disorder},
journal = {Journal of Psychedelic Studies},
year = {2025},
volume = {9},
number = {4},
pages = {320--329},
doi = {10.1556/2054.2025.00461}
}
EUVIMED